<International Circulation>: The OASIS 5 study compared fondaparinux with enoxaparin in patients with STE-ACS and the OASIS 6 study compared fondaparinux with UFH in patients with STEMI. Both of those studies confirmed the safety and efficacy of fondaparinux. The OASIS 8 study compared fondaparinux with UHF during PCI in high risk patients with non-STE-ACS. From the results of these trials and your own experience， what is your understanding of the best anticoagulant strategy for patients presenting with ACS?

 《国际循环》：OASIS 5研究在STE-ACS患者中将磺达肝癸钠与依诺肝素进行了比较，OASIS 6研究则在STEMI患者中对比了磺达肝癸钠和UFH。这些研究均证实了磺达肝癸钠的安全性和有效性。OASIS-8研究在非STE-ACS高危患者PCI期间比较了磺达肝癸钠和UFH。从这些试验的结果以及您个人的经验来看，对ACS患者最佳抗凝策略您有何理解？

    Prof. Jolly: Fondaparinux is an attractive option that is recommended by the guidelines and it is in fact a safe option. Now you have clear recommendations how to treat these patients in the cath lab. You can have a seamless strategy with therapy in the emergency room， to the cath lab， and home. If I were a patient， I would think this were an attractive option.

    Jolly教授：磺达肝癸钠是一个得到指南推荐的有吸引力的选择，实际上也是一个安全的选择。目前，关于在导管室中如何治疗这些患者已经有了明确的推荐。在急诊室、导管室以及家庭中，我们已有一种无缝治疗策略。如果我是一名患者，我会认为这是一个有吸引力的选择。